CD33 and breast cancer: A consistent phenomenon was observed in human breast cancer in which the sustained activation of the JAK/STAT signaling pathway dominated the amplification and immunosuppressive capacity of the Lin−HLA-DR−CD45+CD13+CD33+CD14−CD15− e-MDSCs (8, 9).